BioLargo (BLGO) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 12, 2017
Document Information [Line Items]
Entity Registrant Name	BIOLARGO, INC.
Entity Central Index Key	880,242
Trading Symbol	blgo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		102,364,539
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 1,251,951	$ 1,910,153
Accounts receivable	113,643	67,994
Inventories	39,284	34,446
Prepaid expenses and other current assets	41,623	4,089
Total current assets	1,446,501	2,016,682
Equipment, net of depreciation	55,219	59,315
Other non-current assets, net of amortization	33,939	36,729
Deferred offering costs	205,536
Total assets	1,741,195	2,112,726
Current liabilities:
Accounts payable and accrued expenses	455,547	200,103
Accrued officer bonus		80,000
Convertible notes payable	4,803,847	560,000
Discount on convertible notes payable and line of credit, net of amortization	(1,697,179)	(398,910)
Derivative warrant liability		663,560
Line of credit	50,000	50,000
Total current liabilities	3,612,215	1,154,753
Long-term liabilities:
Convertible notes payable	1,506,771	5,250,668
Discount on convertible notes payable, net of amortization	(976,461)	(3,522,497)
Total liabilities	4,142,525	2,882,924
COMMITMENTS, CONTINGENCIES (Note 11)
STOCKHOLDERS’ DEFICIT:
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2016 and September 30, 2017.
Common stock, $.00067 Par Value, 200,000,000 Shares Authorized, 92,975,970 and 101,734,166 Shares Issued, at December 31, 2016 and September 30, 2017.	68,186	62,179
Additional paid-in capital	95,761,931	90,609,774
Accumulated deficit	(98,862,024)	(91,915,426)
Accumulated other comprehensive loss	(57,951)	(81,694)
Total Biolargo stockholders’ deficit	(3,089,858)	(1,325,167)
Non-controlling interest (Note 9)	688,528	554,969
Total stockholders’ deficit	(2,401,330)	(770,198)
Total liabilities and stockholders’ deficit	$ 1,741,195	$ 2,112,726

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	101,734,166	92,975,970

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues
Product revenue	$ 172,045	$ 107,321	$ 318,040	$ 160,249
License revenue		55,000		55,000
Total revenue	172,045	162,321	318,040	215,249
Cost of revenues	(123,278)	(47,112)	(219,207)	(68,950)
Gross profit:	48,767	115,209	98,833	146,299
Selling, general and administrative expenses	1,117,790	989,223	3,334,863	2,843,694
Research and development	425,670	348,619	1,141,286	1,029,637
Amortization and depreciation	6,647	3,005	21,086	8,580
Total operating expenses:	1,550,107	1,340,847	4,497,235	3,881,911
Operating loss:	(1,501,340)	(1,225,638)	(4,398,402)	(3,735,612)
Other (expense) income:
Interest expense	(848,735)	(1,087,578)	(2,921,564)	(1,972,428)
Change in fair value of derivative warrant liability		(202,110)		(202,110)
Grant income	103,949	31,223	174,098	113,319
Total other expense:	(744,786)	(1,258,465)	(2,747,466)	(2,061,219)
Net loss	(2,246,126)	(2,484,103)	(7,145,868)	(5,796,831)
Net loss attributable to noncontrolling interest	(89,414)	(69,843)	(326,581)	(191,674)
Net loss attributable to common shareholders	$ (2,156,712)	$ (2,414,260)	$ (6,819,287)	$ (5,605,157)
Net loss per share attributable to common shareholders:
Loss per share attributable to shareholders – basic and diluted (in dollars per share)	$ (0.02)	$ (0.03)	$ (0.07)	$ (0.06)
Weighted average number of common shares outstanding: (in shares)	100,752,279	88,148,092	97,679,544	86,809,862
Comprehensive loss:
Net loss	$ (2,246,126)	$ (2,484,103)	$ (7,145,868)	$ (5,796,831)
Foreign currency translation	41,856	(606)	23,743	(9,924)
Comprehensive loss	(2,204,270)	(2,484,709)	(7,122,125)	(5,806,755)
Comprehensive loss attributable to noncontrolling interest	(89,414)	(69,843)	(326,581)	(191,674)
Comprehensive loss attributable to common stockholders	$ (2,114,856)	$ (2,414,866)	$ (6,795,544)	$ (5,615,081)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Chief Executive Officer [Member]Common Stock [Member]	Chief Executive Officer [Member]Additional Paid-in Capital [Member]	Chief Executive Officer [Member]Retained Earnings [Member]	Chief Executive Officer [Member]AOCI Attributable to Parent [Member]	Chief Executive Officer [Member]Noncontrolling Interest [Member]	Chief Executive Officer [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2016							92,975,970
Balance at Dec. 31, 2016							$ 62,179	$ 90,609,774	$ (91,915,426)	$ (81,694)	$ 554,969	$ (770,198)
Stock issued for services - vendors and consultants (in shares)							480,625
Stock issued for services - vendors and consultants							$ 331	251,986				252,317
Stock issued to CEO (Note 5) (in shares)	1,500,000						51,100
Stock issued to CEO (Note 5)	$ 1,005	$ (1,005)					$ 34	22,466				22,500
Payment of interest (in shares)							1,034,762
Payment of interest							$ 821	506,800				507,621
Conversion of notes (in shares)							2,190,774
Conversion of notes							$ 1,468	834,782				$ 836,250
Exercise of warrants (in shares)							510,000					510,000
Exercise of warrants							$ 343	152,657				$ 153,000
Cashless exercise of stock options (in shares)							2,501,937
Cashless exercise of stock options							$ 1,677	(1,677)
Financing fee to Lincoln Park (in shares)							488,998
Financing fee to Lincoln Park							$ 328	205,672				206,000
Stock option compensation expense								801,716				801,716
Fair value of warrants and conversion feature issued as discount on convertible notes payable								1,067,629				1,067,629
Purchase of Clyra shares											(40,000)	(40,000)
Issuance of Clyra shares											500,140	1,020,400
Deemed dividend for anti-dilution trigger (Note 3)								299,111	(299,111)
Cumulative effect from the change in accounting for derivative liability								491,760	171,800			663,560
Net loss									(6,819,287)		(326,581)	(7,145,868)
Foreign currency translation										23,743		23,743
Balance (in shares) at Sep. 30, 2017							101,734,166
Balance at Sep. 30, 2017							$ 68,186	$ 95,761,931	$ (98,862,024)	$ (57,951)	$ 688,528	$ (2,401,330)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (7,145,868)	$ (5,796,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	801,716	645,808
Common stock issued for services — vendors and consultants	252,317	387,806
Common stock issued for payment of interest	507,621	314,937
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	2,315,396	1,577,845
Change in fair value of derivative warrant liability		202,110
Deferred offering cost expense	464
Amortization and depreciation expense	21,086	8,580
Bad debt expense	2,500
Changes in assets and liabilities:
Accounts receivable	(48,149)	(41,856)
Inventories	(4,838)	11,815
Prepaid expenses and other assets	(42,734)	16,913
Accounts payable and accrued expenses	345,844	(62,681)
Officer bonus	(80,000)	100,000
Deposits		(135,000)
Other assets		(28,542)
Net cash used in operating activities	(3,074,645)	(2,799,096)
Cash flows from investing activities
Equipment purchases	(9,000)	(55,349)
Net cash used in investing activities	(9,000)	(55,349)
Cash flows from financing activities
Proceeds from convertible notes	1,266,200	2,190,000
Proceeds from line of credit	250,000	300,000
Proceeds from sale of Clyra stock	750,000
Proceeds from sale of common stock	22,500
Purchase of Clyra shares	(40,000)
Proceeds from exercise of warrants	153,000	355,000
Net cash provided by financing activities	2,401,700	2,845,000
Effect of foreign currency translation	23,743	(21,723)
Net change in cash and cash equivalents	(658,202)	(31,168)
Cash and cash equivalents at beginning of period	1,910,153	1,763,114
Cash and equivalents at end of period	1,251,951	1,731,946
Supplemental disclosures of cash flow information
Interest	6,731	3,551
Income taxes	5,350	6,509
Non-cash investing and financing activities
Conversion of accounts payable into stock options	354,326	272,032
Fair value of warrants issued in conjunction with convertible notes payable	1,067,629	2,460,975
Convertible notes into shares of common stock	836,250	352,566
Stock Issued for Letter of Credit [Member]
Non-cash investing and financing activities
Fair value of stock issued for line of credit	250,000
Stock Issued for Financing Fee [Member]
Non-cash investing and financing activities
Fair value of stock issued for line of credit	206,000
Common Stock Issued for Settlement of Accounts Payable and Interest [Member]
Non-cash investing and financing activities
Fair value of stock issued for line of credit	$ 759,938	$ 702,743

Note 1 - Business and Organizat

Note 1 - Business and Organization	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, for the nine September 30, 2017, $7,145,868, $3,074,645 September 30, 2017, $2,165,714, $1,446,501, $98,862,024. not We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Cash totaled $1,251,951 September 30, 2017 $650,000 December 31, 2016. nine September 30, 2017 $318,040. 100% 2016, 70% three not third 12 7 As of September 30, 2017, $6,360,618 $50,000 4 September 30, 2017, $455,547 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, Accordingly, they do not nine September 30, 2017 not may December 31, 2017, Form 10 December 31, 2016 March 30, 2017. We have seven 2006, No 2009, 2013, 2014, 2016, 2016, 2017. 46.3% 2012 9

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries and entities in which management believes it has a controlling interest. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based compensation , equity components of financing transactions, uncollectible accounts receivable, asset impairment and amortization, and taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the consolidated financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting. Warrants The Unit Offerings of our convertible promissory note and a Series A stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first not. If the warrant is determined to not The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) which the effective convertible price of the note is less than the closing stock price on date of issuance. The adjusted BCF value is accounted for as equity. The warrant and BCF fair values are also recorded as a discount to the convertible promissory notes. The equity features of the convertible promissory notes resulted in a discount to the convertible notes that is equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may one Government Grants We have been awarded grants from government and industry orgnaizations in the United States and Canada. The government grants received are considered Other Income and are included in our consolidated statements of operations. We received our first n 2015 fifty $1,100,000. third six eighteen not The grants provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost r eimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2016 2017, Cash and cash equivalents The Company considers all highly liquid investments with maturities of three one in the United States. From time to time, our cash account balances are greater than the Federal Deposit Insurance Corporation insurance limit of $250,000 not Our cash balances were made up of the following: DECEMBER 31, 2016 SEPTEMBER 30, 2017 Biolargo, Inc. and wholly owned subsidiaries $ 1,671,857 $ 431,034 Clyra Medical Technologies, Inc. 238,296 820,917 Total $ 1,910,153 $ 1,251,951 Allowance for uncollectible receivables Management evaluates credit quality by evaluating the exposure to individual counterparties, and, where warranted, management also considers the credit rating or financial position, operating results and/or payment history of the counterparty. Management establishes an allowance for amounts for which collection is considered doubtful. Adjustments to previous assessments are recognized in income in the period in which they are determined. At September 30, 2017, $2,500. Recent Accounting Pronou ncements In July 2017, “ASU”) No. 2017 11, 260 480 815 815 no December 15, 2018. July 1, 2017. ( 3. In April 2016, 2016 10, 606 2014 09, Revenue from Contracts with Customers (Topic 606 December 15, 2017. Management’s current analysis is that the new guidelines currently will not In March 2016, No. 2016 09, Improvements to Employee Share-Based Payment Accounting,” which simplifies several aspects of the accounting for share-based award transactions and adds two December 15, 2017. not In February 2016, No. 2016 02, ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 December 15, 2018, two 12

Note 3 - Change in Derivative L

Note 3 - Change in Derivative Liability Treatment	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounting Changes [Text Block]	Note 3. As discussed in Note 2, Recent Accounting Pronouncements”, Biolargo has adopted ASU 2017 11 July 1, 2017. January 1, 2017, $663,560. May 2017, $216,000 September 2017, $83,111

Note 4 - Convertible Notes Paya

Note 4 - Convertible Notes Payable and Lines of Credit	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. DECEMBER 31, 201 6 SEPTEMBER 3 0 , 201 7 Current liabilities: Line of credit $ 50,000 $ 50,000 Convertible notes payable One-Year Convertible notes, mature July 8, 2017 $ 280,000 $ — One-Year Convertible notes, mature December 30, 2017 280,000 — One-Year Convertible notes, mature July 18, 2018 — 280,000 Convertible notes, mature June 1, 2018* — 4,523,847 Total convertible notes payable $ 560,000 $ 4,803,847 Long-term liabilities: Convertible notes payable, net of current portion Convertible notes, mature June 1, 2018* $ 4,800,097 $ — Convertible notes, mature September 17, 2019 283,571 283,571 Convertible notes, mature December 31, 2019 167,000 292,000 Convertible notes, mature July 20, 2019 — 440,000 Convertible notes, mature June 20, 2020 — 491,200 Total convertible notes payable , net of current portion $ 5,250,668 $ 1,506,771 Total $ 5,860,668 $ 6,360,618 * The convertible notes that mature June 1, 2018, December 31, 2016, one June 30, 2017. For the three nine September 30, 2016, $1,087,578 $1,972,428 three nine September 30, 2017, $848,735 $2,921,564 Line of Credit On June 6, 2016, $300,000 18% At any time after December 1, 2017, may 30 no 6. one On September 17, 2016, $250,000 2015 As of December 31, 2016, September 30, 2017, $50,000 One-Year Convertible N otes, mature July 8, 2017 On July 8, 2016, $250,000 $0.45 July 8, 2017 two ’ in the aggregate principal amount of $280,000. 3% 400,000 $0.65 five 6. On January 13, 2017, $280,000 640,889 One-Year Convertible Note s , mature December 30, 2017 On December 30, 2016, $250,000 $0.57 December 30, 2017 two $280,000. Interest was charged upon issuance at 3% two 400,000 $0.75 five 6. The notes contain a conversion price protection feature such that if the company issues a convertible promissory note at a lower conversion price, the holder may July 18, 2017, $0.42 July 18, 2018,” $0.57 $0.42. 686,667 One-Year Convertible Notes, mature July 18, 2018 On July 18, 2017, $250,000 promissory notes (convertible at $0.42 July 18, 2018 two $280,000. 3% January 18, 2018, two 10 may We also issued these investors stock purchase warrants to purchase an aggregate 400,000 common stock exercisable at $0.65 five 6. Convertible Notes, mature June 1, 2018 ( 2015 On January 15, 2015, “2015 September 16, 2016. five ’s common stock at the Unit price set forth in the particular pricing supplement, and matures June 1, 2018. Interest due may ’s common stock over the 20 may may ten three June 15, 2017, Each investor, for no 6 As of September 30, 2017, 2015 June 1, 2018 Unit/ Conversion Price Warrant Exercise Price Total $ 0.25 $ 0.40 $ 1,626,134 $ 0.35 $ 0.45 1,751,046 $ 0.55 $ 0.70 1,146,667 $ 4,523,847 During the nine September 30, 2017, $276,250 2015 883,218 During the nine September 30, 2016, $1,940,000, June 1, 2018, 12% Clyra Line of Credit, matures March 31, 2019 On March 31, 2017, our subsidiary Clyra (see Note 9 $250,000 10% 5% On July 22, 2017, $250,000 of Clyra common stock at a price per share equal to that offered to investors in the Clyra offering (see Note 9 $270,400. 1,690 $160 Convertible Notes, mature September 17, 2019 On September 17, 2016, December 1, 2017,” $250,000 $33,571 $0.55 September 17, 2019, 2015 $0.70 September 17, 2016. 515,583 $0.70 6 Convertible Notes, mature December 31, 2019 (Winter 2016 On December 27, 2016, 2016 $600,000 $0.57 $0.86, December 31, 2019, 12% ’s common stock over the 20 may When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the $0.57 may ’s common stock closes for ten three $0.57 one $0.70 December 31, 2021 ( 6 may 30 10 two 1 January 24, 2017. From inception of the offering through it s termination on January 13, 2017, $292,000 six $292,000, 512,281 Convertible Notes, mature June 20, 2020 (Summer 2017 On May 24, 2017, 2017 $1,500,000 convertible at $0.42 June 20, 2020, 12% 20 may When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the $0.42 may ’s common stock closes for ten three $0.42 one $0.65 June 20, 2022 ( 6 may 30 10 two Through September 30, 2017, received $491,200 nine 1,169,525 Two-Year Convertible Note , matures July 20, 2019 On July 20, 2017, $400,000 10% $440,000, two 12% ’s option, into either BioLargo common shares at $0.42 2,000 $0.42 may $171,429 July 20, 2019.

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Common Stock On May 2, 2017, Company’s president, Dennis Calvert (see Note 11 1,500,000 $3,000,000 $3,000,000 12 Stock Option Expense During the three nine September 30, 2017, $285,757 $801,716, three nine September 30, 2016, $154,368 $645,808, 2007 2007 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may 10 September 7, 2017. O n June 19, 2017, 40,000 2007 $0.43 $15,600 On February 10, 2017, our engagement agreement with our Chief Financial Officer. The sole consideration for the one 300,000 $0.69 February 10, 2027, 125,000 February 10, 2017, 25,000 March 1, 2017, $207,000, three nine September 30, 2017, $51,750 $207,000, On June 2 0, 2016, 40,000 2007 $0.45 $18,000 On March 21, 2016, y five 307,777 March 2011. March 21, 2021. $119,971 Activity for our stock options under the 2007 for the nine September 30, 2016 2017 Weighted Balance, September 30, 2016: Average Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2015 10,241,086 1,758,914 $0.22 – 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Expired (262,500 ) 262,500 0.40 0.40 Balance , September 30, 2016 10,018,586 1,981,414 $0.22 – 1.89 $ 0.46 Weighted Average Balance, September 30, 2017: Options Exercise Price per Outstanding Price per share share Balances as of December 31, 2016 9,916,586 $0.22 – 1.89 $ 0.44 Granted 340,000 0.39 – 0.69 0.65 Exercised — — — Balance , September 30, 2017 10,256,586 $0.22 – 1.89 $ 0.44 Options issued Outside of the 2007 During the three nine September 30, 2017, 132,354 407,704 $0.43 – $0.51 three nine September 30, 2017 $67,500 $202,500, During the three nine September 30, 2017, 144,317 689,846 $0.43 – $0.67 three nine September 30, 2017 $45,402 $187,476, On September 5, 2017, 2,000,000 10 $0.45 rice of our common stock as of September 5th, ten five five 10 $900,000. not September 2018 On May 2, 2017, is employment agreement (see Note 11 3,731,322 $0.45 May 2nd, ten five not $1,679,095 May 2, 2022. three nine September 30, 2017, $83,955 $111,940, During the three nine September 30, 2016, 422,896 906,973 $0.33 $0.76 three nine September 30, 2016, $77,418 $430,887, The fair value of the options issued prior to 2016 three nine September 30, 2016, $0 $170,310, three nine September 30, 2017, $37,150 $77,200, Exercise of Stock Option On April 30, 2017, our president, Dennis P. Calvert, delivered a notice of exercise of 3,866,630 April 30, 2007. $0.18 2,501,937 $0.51 $0.18 No 3,866,629 Pursuant to a “lock-up agreement” dated April 30, 2017, ’s products or technologies as demonstrated by its receipt of at least $3,000,000 $3,000,000 12 May 2, 2017 Activity of our stock options issued outside of the 2007 nine September 30, 2016 2017 Weighted Balance, September 30, 2016: Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2015 19,394,975 $0.18 – 1.00 $ 0.40 Granted 484,077 0.33 – 0.45 0.38 Exercised (60,000 ) 0.25 0.25 Balance , September 30, 2016 19,819,052 $0.18 – 1.00 $ 0.41 Weighted Average Balance, September 30, 2017: Options Exercise Price per Outstanding Price per share share Balance, December 31, 2016 20,148,766 $0.18 – 1.00 $ 0.40 Granted 6,828,872 0.43 – 0.67 0.46 Expired (3,866,629 ) 0.18 0.18 Exercised (3,866,630 ) 0.18 0.18 Balance , September 30, 2017 19,244,379 $0.18 – 1.00 $ 0.51 We recognize employee compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the nine September 30: 2016 2017 Non Place 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.77 – 2,27% 1.36 – 1.77% 2.29 – 2.40% 2.31 – 2.40% Expected volatility 641 – 738% 315 – 641% 571 – 601% 578 – 601% Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 5 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not

Note 6 - Warrants

Note 6 - Warrants	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Warrants [Text Block]	Note 6. Warrants Issued to Summer 2017 Pursuant to the terms of our Summer 2017 4 1,169,525 $0.65 238,096 three June 30, 2017, 931,429 three September 30, 2017. June 20, 2022. $491,200 Warrants Issued to Winter 2016 Pursuant to the terms of our Winter 2016 4 512,281 exercise price of $0.70 292,983 three December 30, 2016, 219,298 three March 31, 2017. December 31, 2021. $125,000 no Warran ts Issued Concurrently with One-Year Convertible Notes On July 8, 2016, 400,000 to two one July 8, 2017 ( 4 $0.65 July 8, 2021. $160,000 one may 2015 May 24, 2017, 2017 $0.42 4 July 8, 2016 $0.65 $0.42 219,048 619,048 On December 30, 2016 400,000 to two one December 30, 2017 ( 4 $0.75 December 31, 2021. $0.83. $280,000 one may 2016 May 24, 2017, 2017 $0.42 4 December 30, 2016 $0.75 $0.42 314,285 714,285 On July 18, 2017, 400,000 two one July 18, 2018 ( 4 $0.65 per share and expire July 31, 2022. may 2017 two $280,000 July 18, 2022. September 26, 2017, 7 $0.65 $0.42 177,777 577,777 These warrants are no 2015 During the nine months ended September 30, 2016, 4,455,413 2015 4 2,719,048 $0.45 1,736,365 $0.70 June 1, 2020. $1,940,000 Warrants Issued C oncurrently with Line of Credit During the nine September 30, 2016, 300,000 4 $0.35 June 2021. The relative fair value of warrants issued resulted in $237,405 Pursuant to the terms of our line of credit, five 2015 ing $283,571 4 515,583 $0.70 June 1, 2018. $283,571 Exercise of Warrants During the nine September 30, 2017, 510,000 $153,000 During the three months ended September 30, 2016, 1,150,000 $355,000 We have certain warrants outstanding to purchase our common stock, at various prices, as summarized in the following tables: Balance, September 30, 2016 Number of Shares Price Range Outstanding as of December 31, 20 15 13,779,438 $0.125 – 1.00 Issued 5,670,996 0.35 – 0.70 Exercised (1,150,000 ) 0.30 – 0.45 Expired (263,545 ) 0.55 – 0.75 Outstanding as of September 30, 2016 18,036,889 $0.125 – 1.00 Balance, September 30, 201 7 Number of Shares Price Range Outstanding as of December 31, 2016 20,035,114 $0.125 – 1.00 Issued 2,499,933 0.42 – 0.70 Exercised (510,000 ) 0.30 Expired (250,000 ) 0.25 – 0.30 Outstanding as of September 30, 2017 21,775,047 $0.125 – 1.00 T he fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows for the nine September 30: 2016 2017 Risk free interest rate 0.95 – 1.36% 1.71 – 1.93% Expected volatility 311 – 315% 293 – 297% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 5 The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock.

Note 7 - Lincoln Park Transacti

Note 7 - Lincoln Park Transaction	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 7. On August 25, 2017, Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has agreed to purchase from us at our request up to an aggregate of $10,000,000 three 1 1933, may September 22, 2017, 50,000 $0.50 75,000 $0.50 $0.74 100,000 $0.75 $1.24 200,000 $1.25 $500,000. no may three 12 may one no first may not In consideration for entering into the Purchase Agreement, on August 25, 2017, 488,998 initial commitment fee.” For no $10,000,000 488,998 $25,000 1,222 $25,000 $10,000,000 488,998 During the three September 30, 2017, 50,000 $22,500, 51,100 50,000 1,100 Subsequent to September 30, 2017, 12.

Note 8 - Accounts Payable and A

Note 8 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 8. Accounts payable and accrued expenses included the following: December 31, September 30 , 2016 2017 Accounts payable and accrued expenses $ 22,231 $ 277,411 Payroll tax liability 137,500 137,500 Accrued officer bonus 80,000 — Accrued interest 40,372 40,636 Total accounts payable and accrued expenses $ 280,103 $ 455,547 The payroll tax liability is the Company ’s estimate of payroll taxes due on the past services of independent contractors. The Company is currently attempting to reduce the liability to approximately $5,000 On September 27, 2016, $60,000 $20,000 2016. $40,000 January 2017.

Note 9 - Noncontrolling Interes

Note 9 - Noncontrolling Interest - Clyra Medical	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 9. In May 2012, Clyra”). We initially owned 100% 85% On December 30, 2015, Preferred Shares”) to Sanatio Capital, LLC (“Sanatio”) for $750,000. 40% 54%, three June 2017, As set forth in Clyra ’s Amended and Restated Articles of Incorporation, Preferred Shares accrue an annual dividend of 8% five no 510 December 20, September 30, 2017 $105,000. Holders of Preferred Shares are entitled to preferential payments in the event of a liquidation, dissolution or winding up of the company, in an amount equal to any accrued and unpaid dividends. After such preference, any remaining assets are distributed pro-rata between holders of Clyra common stock and Preferred Shares as if the Preferred Shares had converted to Clyra common stock. Holders of Preferred Shares may one one In addition to the foregoing, Clyra entered into a consulting agreement with Beach House Consulting, LLC, through which Jack B. Strommen will be providing consulting services to the company. Mr. Strommen will be assisting the company in its sales and mark eting activities once it has FDA Approval on a product, at which point the agreement provides that Mr. Strommen is to receive $23,438 four In April 2017, 500 ’s management. In August 2017, $160 $1,000,000 6,250 two $250,0 00 1,562.5 August 4, 2017, 1,690 15,297.5 46.3% three On September 27, 2017, 510 90

Note 10 - Biolargo Engineering,

Note 10 - Biolargo Engineering, Science and Technologies, LLC	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 10 . Biolargo Engineering, Science and Technologies, LLC In September 2017, three 11 seven $100,000 The company was capitalized with two 100% no five 30% 2,000,000 five tied to the performance of the subsidiary, including gross revenue targets that increase over time, obtaining positive cash flow by March 31, 2018, 90% 10% first 8 September 8, 2017.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies.	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11. Calvert Employment Agreement On May 2, 2017, with its President and Chief Executive Officer Dennis P. Calvert (the “Calvert Employment Agreement”), replacing in its entirety the previous employment agreement with Mr. Calvert dated April 30, 2007. The Calvert Employment Agreement provides that Mr. Calvert will continue to serve as our President and Chief Executive Officer and receive base compensation equal to his current rate of pay of $288,603 $800 four may The Calvert Employment Agreement provides that Mr. Calvert will be granted an option (the “Option”) to purchase 3,731,322 $0.45 ten five not 1,500,000 $3,000,000 $3,000,000 12 BIOLARGO, INC. AND SUBSIDIARIE S NOTES TO CONSOLIDATED FINANCIAL STATEMENT S (UNAUDITED ) The Calvert Employment Agreement has a term of five Calvert’s employment may 120 360 nolo contendre one one one one The Calvert Employment Agreement requires Mr. Calvert to keep certain information confidential, not Office Leases We are parties to three Our Westminster lease rquires a monthly payment of $8,630 3% September 1 st September 1, 2020. $5,400 September 1, 2020. CAD$5,130 June 30, 2018. October 1, 2017, $500,477 CAD$46,170 Clyra Consulting Agreement Our partially owned subsidiary Clyra (see Note 9 received FDA Approval (as defined in Note 9 $23,438 four $1,125,024.

Note 12 - Subsequent Events.

Note 12 - Subsequent Events.	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure. Lincoln Park Capital Subsequent to October 1, 2017, November 8, 2017, 675,000 7 $308,745 15,097

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries and entities in which management believes it has a controlling interest. All intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based compensation , equity components of financing transactions, uncollectible accounts receivable, asset impairment and amortization, and taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the consolidated financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
Warrant Policy [Policy Text Block]	Warrants The Unit Offerings of our convertible promissory note and a Series A stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first not. If the warrant is determined to not The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) which the effective convertible price of the note is less than the closing stock price on date of issuance. The adjusted BCF value is accounted for as equity. The warrant and BCF fair values are also recorded as a discount to the convertible promissory notes. The equity features of the convertible promissory notes resulted in a discount to the convertible notes that is equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may one
Government Grants [Policy Text Block]	Government Grants We have been awarded grants from government and industry orgnaizations in the United States and Canada. The government grants received are considered Other Income and are included in our consolidated statements of operations. We received our first n 2015 fifty $1,100,000. third six eighteen not The grants provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost r eimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2016 2017,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid investments with maturities of three one in the United States. From time to time, our cash account balances are greater than the Federal Deposit Insurance Corporation insurance limit of $250,000 not Our cash balances were made up of the following: DECEMBER 31, 2016 SEPTEMBER 30, 2017 Biolargo, Inc. and wholly owned subsidiaries $ 1,671,857 $ 431,034 Clyra Medical Technologies, Inc. 238,296 820,917 Total $ 1,910,153 $ 1,251,951
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for uncollectible receivables Management evaluates credit quality by evaluating the exposure to individual counterparties, and, where warranted, management also considers the credit rating or financial position, operating results and/or payment history of the counterparty. Management establishes an allowance for amounts for which collection is considered doubtful. Adjustments to previous assessments are recognized in income in the period in which they are determined. At September 30, 2017, $2,500.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronou ncements In July 2017, “ASU”) No. 2017 11, 260 480 815 815 no December 15, 2018. July 1, 2017. ( 3. In April 2016, 2016 10, 606 2014 09, Revenue from Contracts with Customers (Topic 606 December 15, 2017. Management’s current analysis is that the new guidelines currently will not In March 2016, No. 2016 09, Improvements to Employee Share-Based Payment Accounting,” which simplifies several aspects of the accounting for share-based award transactions and adds two December 15, 2017. not In February 2016, No. 2016 02, ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 December 15, 2018, two 12

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	DECEMBER 31, 2016 SEPTEMBER 30, 2017 Biolargo, Inc. and wholly owned subsidiaries $ 1,671,857 $ 431,034 Clyra Medical Technologies, Inc. 238,296 820,917 Total $ 1,910,153 $ 1,251,951

Note 4 - Convertible Notes Pa21

Note 4 - Convertible Notes Payable and Lines of Credit (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	DECEMBER 31, 201 6 SEPTEMBER 3 0 , 201 7 Current liabilities: Line of credit $ 50,000 $ 50,000 Convertible notes payable One-Year Convertible notes, mature July 8, 2017 $ 280,000 $ — One-Year Convertible notes, mature December 30, 2017 280,000 — One-Year Convertible notes, mature July 18, 2018 — 280,000 Convertible notes, mature June 1, 2018* — 4,523,847 Total convertible notes payable $ 560,000 $ 4,803,847 Long-term liabilities: Convertible notes payable, net of current portion Convertible notes, mature June 1, 2018* $ 4,800,097 $ — Convertible notes, mature September 17, 2019 283,571 283,571 Convertible notes, mature December 31, 2019 167,000 292,000 Convertible notes, mature July 20, 2019 — 440,000 Convertible notes, mature June 20, 2020 — 491,200 Total convertible notes payable , net of current portion $ 5,250,668 $ 1,506,771 Total $ 5,860,668 $ 6,360,618
Convertible Debt [Table Text Block]	Unit/ Conversion Price Warrant Exercise Price Total $ 0.25 $ 0.40 $ 1,626,134 $ 0.35 $ 0.45 1,751,046 $ 0.55 $ 0.70 1,146,667 $ 4,523,847

Note 5 - Share-based Compensa22

Note 5 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Balance, September 30, 2016: Average Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2015 10,241,086 1,758,914 $0.22 – 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Expired (262,500 ) 262,500 0.40 0.40 Balance , September 30, 2016 10,018,586 1,981,414 $0.22 – 1.89 $ 0.46 Weighted Average Balance, September 30, 2017: Options Exercise Price per Outstanding Price per share share Balances as of December 31, 2016 9,916,586 $0.22 – 1.89 $ 0.44 Granted 340,000 0.39 – 0.69 0.65 Exercised — — — Balance , September 30, 2017 10,256,586 $0.22 – 1.89 $ 0.44
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2017 Non Place 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.77 – 2,27% 1.36 – 1.77% 2.29 – 2.40% 2.31 – 2.40% Expected volatility 641 – 738% 315 – 641% 571 – 601% 578 – 601% Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 5 7 7
Outside of 2007 Plan [Member]
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Balance, September 30, 2016: Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2015 19,394,975 $0.18 – 1.00 $ 0.40 Granted 484,077 0.33 – 0.45 0.38 Exercised (60,000 ) 0.25 0.25 Balance , September 30, 2016 19,819,052 $0.18 – 1.00 $ 0.41 Weighted Average Balance, September 30, 2017: Options Exercise Price per Outstanding Price per share share Balance, December 31, 2016 20,148,766 $0.18 – 1.00 $ 0.40 Granted 6,828,872 0.43 – 0.67 0.46 Expired (3,866,629 ) 0.18 0.18 Exercised (3,866,630 ) 0.18 0.18 Balance , September 30, 2017 19,244,379 $0.18 – 1.00 $ 0.51

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Balance, September 30, 2016 Number of Shares Price Range Outstanding as of December 31, 20 15 13,779,438 $0.125 – 1.00 Issued 5,670,996 0.35 – 0.70 Exercised (1,150,000 ) 0.30 – 0.45 Expired (263,545 ) 0.55 – 0.75 Outstanding as of September 30, 2016 18,036,889 $0.125 – 1.00 Balance, September 30, 201 7 Number of Shares Price Range Outstanding as of December 31, 2016 20,035,114 $0.125 – 1.00 Issued 2,499,933 0.42 – 0.70 Exercised (510,000 ) 0.30 Expired (250,000 ) 0.25 – 0.30 Outstanding as of September 30, 2017 21,775,047 $0.125 – 1.00
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	2016 2017 Risk free interest rate 0.95 – 1.36% 1.71 – 1.93% Expected volatility 311 – 315% 293 – 297% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 5

Note 8 - Accounts Payable and24

Note 8 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, September 30 , 2016 2017 Accounts payable and accrued expenses $ 22,231 $ 277,411 Payroll tax liability 137,500 137,500 Accrued officer bonus 80,000 — Accrued interest 40,372 40,636 Total accounts payable and accrued expenses $ 280,103 $ 455,547

Note 1 - Business and Organiz25

Note 1 - Business and Organization (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Aug. 04, 2017	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (2,246,126)	$ (2,484,103)	$ (7,145,868)	$ (5,796,831)
Net Cash Provided by (Used in) Operating Activities			(3,074,645)	(2,799,096)
Working Capital	(2,165,714)		(2,165,714)
Assets, Current	1,446,501		1,446,501			$ 2,016,682
Retained Earnings (Accumulated Deficit)	(98,862,024)		(98,862,024)			(91,915,426)
Cash and Cash Equivalents, at Carrying Value	1,251,951	1,731,946	1,251,951	1,731,946		$ 1,910,153	$ 1,763,114
Cash and Cash Equivalents, Period Increase (Decrease)			(658,202)	(31,168)
Revenue, Net	172,045	$ 162,321	318,040	$ 215,249
Long-term Debt, Gross	6,360,618		6,360,618
Convertible Debt	50,000		50,000
Accounts Payable and Accrued Liabilities	$ 455,547		$ 455,547
Number of Wholly-Owned Subsidiaries	7		7
Clyra [Member]
Noncontrolling Interest, Ownership Percentage by Parent	46.30%		46.30%		46.30%

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies (Details Textual)	9 Months Ended
	Sep. 30, 2017USD ($)
Allowance for Doubtful Accounts, Premiums and Other Receivables	$ 2,500
Canadian Government Grants [Member]
Number of Grants Received	50
Grants Receivable	$ 1,100,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term	180 days
Canadian Government Grants [Member] | Maximum [Member]
Grant Term	1 year 180 days

Note 2 - Summary of Significa27

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Cash and Cash Equivalents, at Carrying Value	$ 1,251,951	$ 1,910,153	$ 1,731,946	$ 1,763,114
Parent Company [Member]
Cash and Cash Equivalents, at Carrying Value	431,034	1,671,857
Noncontrolling Interest [Member]
Cash and Cash Equivalents, at Carrying Value	$ 820,917	$ 238,296

Note 3 - Change in Derivative28

Note 3 - Change in Derivative Liability Treatment (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2017	May 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Deemed Dividend for the Change in Accounting for Derivative Liability			$ (89,414)	$ (69,843)	$ (326,581)	$ (191,674)
Accounting Standards Update 2017-11 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	$ 663,560		$ 663,560		$ 663,560
Deemed Dividend for the Change in Accounting for Derivative Liability	$ 83,111	$ 216,000

Note 4 - Convertible Notes Pa29

Note 4 - Convertible Notes Payable and Lines of Credit (Details Textual)	Aug. 04, 2017USD ($)$ / sharesshares	Jul. 22, 2017USD ($)$ / sharesshares	Jul. 20, 2017USD ($)$ / shares	Jul. 18, 2017USD ($)$ / sharesshares	May 24, 2017USD ($)$ / sharesshares	Jan. 13, 2017USD ($)shares	Jan. 13, 2017USD ($)shares	Dec. 30, 2016USD ($)$ / sharesshares	Dec. 27, 2016USD ($)$ / sharesshares	Sep. 17, 2016USD ($)$ / sharesshares	Jul. 08, 2016USD ($)$ / sharesshares	Jun. 06, 2016USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / shares	Sep. 26, 2017$ / sharesshares	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Interest Expense, Debt													$ 848,735	$ 1,087,578		$ 2,921,564	$ 1,972,428
Proceeds from Lines of Credit												$ 300,000
Line of Credit Facility, Interest Rate During Period												18.00%
Debt Conversion, Original Debt, Amount																354,326	272,032
Line of Credit, Current													$ 50,000		$ 50,000	50,000				$ 50,000
Debt Instrument, Convertible, Conversion Price | $ / shares										$ 0.55
Debt Conversion, Converted Instrument, Amount																$ 836,250	352,566
Share Price | $ / shares								$ 0.83	$ 0.86	$ 0.70
Winter 2016 Unit Offering [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 0.57
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						512,281	512,281
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 0.70
Units Issued During Period, Value, New Issues									$ 600,000
Number of Trading Days Prior to Interest Payment Due Date if Paid by Issuance of Common Stock									20 days
Debt Conversion before Maturity, Number of Trading Days Common Stock Closes at or above 3 Times the Unit Price									10 days
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares									1
Class of Warrant or Right, Exercise Period									30 days
Class of Warrant or Right, Exercise Period Condition, Number of Trading Days Common Stock Closes at or above 2 Times the Exercise Price									10 days
Proceeds from Issuance of Units						$ 292,000
Clyra Medical Technology Inc [Member]
Stock Issued During Period, Shares, New Issues | shares	6,250
Shares Issued, Price Per Share | $ / shares	$ 160
Proceeds from Issuance of Private Placement	$ 1,000,000
Clyra Medical Technology Inc [Member] | Sanatio [Member]
Debt Instrument, Interest Rate, Stated Percentage																			10.00%
Line of Credit Facility, Maximum Borrowing Capacity																			$ 250,000
Original Issue Discount, Percentage																			5.00%
Sanatio [Member]
Debt Conversion, Converted Instrument, Amount		$ 250,000
Long-term Line of Credit		$ 270,400
Stock Issued During Period, Shares, New Issues | shares	1,690	1,690
Shares Issued, Price Per Share | $ / shares		$ 160
The 2015 Unit Offering [Member]
Proceeds from Convertible Debt																	$ 1,940,000
Debt Instrument, Convertible, Conversion Price | $ / shares													$ 4,523,847		$ 4,523,847	$ 4,523,847
Debt Instrument, Interest Rate, Stated Percentage														12.00%			12.00%
Warrants Issued Concurrently With One Year Convertible Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				400,000				400,000			400,000							577,777
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.65	$ 0.42			$ 0.75			$ 0.65							$ 0.42
Class of Warrant or Right, Expiration Term				5 years				5 years			5 years
Warrant Issued in Exchange of Cancelled Line of Credit [Member]
Debt Conversion, Original Debt, Amount																	$ 515,583
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares										515,583
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares										$ 0.70				$ 0.70			$ 0.70
Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares													1,169,525		1,169,525	1,169,525
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 0.65
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares					1
Class of Warrant or Right, Exercise Period					30 days
Class of Warrant or Right, Exercise Period Condition, Number of Trading Days Common Stock Closes at or above 2 Times the Exercise Price					10 days
Proceeds from Issuance of Units															$ 491,200
One Year Convertible Notes [Member]
Debt Conversion, Original Debt, Amount							$ 280,000
Proceeds from Convertible Debt				$ 250,000				$ 250,000			$ 250,000
Debt Instrument, Convertible, Conversion Price | $ / shares				$ 0.42				$ 0.57			$ 0.45
Debt Instrument, Face Amount				$ 280,000				$ 280,000			$ 280,000
Debt Instrument, Interest Rate, Stated Percentage				3.00%				3.00%			3.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.65
Debt Conversion, Converted Instrument, Shares Issued | shares							640,889
Debt Instrument, Convertible, Stock Price Trigger | $ / shares				$ 2				$ 2
Debt Instrument, Convertible, Number of Equity Instruments			686,667
Debt Instrument, Convertible, Threshold Consecutive Trading Days				10
Summer 2017 Unit Offering [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 0.42
Debt Instrument, Interest Rate, Stated Percentage					12.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 0.42
Number of Trading Days Prior to Interest Payment Due Date if Paid by Issuance of Common Stock					20 days
Debt Conversion before Maturity, Number of Trading Days Common Stock Closes at or above 3 Times the Unit Price					10 days
Proceeds from Issuance of Private Placement					$ 1,500,000
Two Year Convertible Note [Member]
Proceeds from Convertible Debt			$ 400,000
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 0.42
Debt Instrument, Face Amount			$ 440,000
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument, Convertible, Number of Equity Instruments			2,000
Debt Instrument, Discount Percent			10.00%
Debt Instrument, Unamortized Discount			$ 171,429
Conversion of Line of Credit to 2015 Unit Offering [Member]
Debt Conversion, Original Debt, Amount										$ 250,000
Debt Conversion, Original Debt, Accrued Interest Amount										$ 33,571
Promissory Notes Issued in 2015 Unit Offering and Accrued Interest Into Common Stock [Member]
Debt Conversion, Original Debt, Amount																$ 276,250
Debt Conversion, Converted Instrument, Shares Issued | shares																883,218

Note 4 - Convertible Notes Pa30

Note 4 - Convertible Notes Payable and Lines of Credit - Schedule of Debt (Details) - USD ($)		Sep. 30, 2017	Dec. 31, 2016
Line of Credit, Current		$ 50,000	$ 50,000
Convertible notes, Current		4,803,847	560,000
Convertible notes		1,506,771	5,250,668
Total		6,360,618	5,860,668
Convertible Notes Maturing on July 8, 2017 [Member]
Convertible notes, Current			280,000
Convertible Notes Maturing on December 30, 2017 [Member]
Convertible notes, Current			280,000
Convertible Notes Maturing on July 18, 2018 [Member]
Convertible notes, Current		280,000
Convertible Notes Maturing on June 1, 2018 [Member]
Convertible notes, Current	[1]	4,523,847
Convertible notes	[1]		4,800,097
Convertible Notes Maturing on September 17, 2019 [Member]
Convertible notes		283,571	283,571
Convertible Notes Maturing on December 31, 2019 [Member]
Convertible notes		292,000	167,000
Convertible Notes Maturing on July 20, 2019 [Member]
Convertible notes		440,000
Convertible Notes, Maturing on June 20, 2020 [Member]
Convertible notes		$ 491,200
[1]	The convertible notes that mature June 1, 2018, were considered “long-term” liabilities as of December 31, 2016, and “current” liabilities (due within one year) as of June 30, 2017. As such, those same liabilities are in both the “long-term” and “current” liabilities section in the above table.

Note 4 - Convertible Notes Pa31

Note 4 - Convertible Notes Payable and Lines of Credit - Pricing Supplements (Details) - $ / shares	Sep. 30, 2017	Sep. 17, 2016
Warrant exercise price (in dollars per share)		$ 0.55
The 2015 Unit Offering [Member]
Warrant exercise price (in dollars per share)	$ 4,523,847
The 2015 Unit Offering [Member] | Pricing Supplement No.1 [Member]
Warrant exercise price (in dollars per share) (in dollars per share)	0.40
Warrant exercise price (in dollars per share)	1,626,134
The 2015 Unit Offering [Member] | Pricing Supplement No.2 [Member]
Warrant exercise price (in dollars per share) (in dollars per share)	0.45
Warrant exercise price (in dollars per share)	1,751,046
The 2015 Unit Offering [Member] | Pricing Supplement No.3 [Member]
Warrant exercise price (in dollars per share) (in dollars per share)	0.70
Warrant exercise price (in dollars per share)	$ 1,146,667

Note 5 - Share-based Compensa32

Note 5 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, xbrli-pure in Thousands	Sep. 05, 2017	Jun. 19, 2017	May 02, 2017	Apr. 30, 2017	Feb. 10, 2017	Jun. 20, 2016	Mar. 21, 2016	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 07, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 30, 2016	Dec. 27, 2016	Sep. 17, 2016
Share Price														$ 0.83	$ 0.86	$ 0.70
Employee Stock Option [Member]
Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate												0.00%
The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												340,000	40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price												$ 0.65	$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period													262,500
The 2007 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											10 years
Outside of the 2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												6,828,872	484,077
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price												$ 0.46	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 37,150	$ 0		$ 77,200	$ 170,310
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period												3,866,629
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense									285,757	154,368		$ 801,716	645,808
Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense							$ 119,971
President and Chief Executive Officer [Member]
Employment Agreement, Common Stock, Expect to Grant, Subject to Lock-Up Agreement			1,500,000
Employment Agreement, Lock-up Agreement, Successful Commercialization, Minimum Cash Receipt			$ 3,000,000
Employment Agreement, Lock-up Agreement, Minimum Revenue Recognized			$ 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Employment Agreement, Term			5 years
Employment Agreement, Option, Number of Shares, Expected to Grant			3,731,322
President and Chief Executive Officer [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.45
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value			$ 1,679,095
President and Chief Executive Officer [Member] | 2007 Stock Option [Member]
Stock Issued During Period, Shares, New Issues				3,866,630
Investment Options, Exercise Price				$ 0.18
Share Price				$ 0.51
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period				3,866,629
President and Chief Executive Officer [Member] | Shares Issued for the Exercise of 2007 Stock Option [Member]
Stock Issued During Period, Shares, New Issues				2,501,937
President and Chief Executive Officer [Member] | Selling, General and Administrative Expenses [Member] | Non-Qualified Stock Option [Member]
Allocated Share-based Compensation Expense									83,955			111,940
Non-employee Members of the Board of Directors [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		40,000				40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.43				$ 0.45
Non-employee Members of the Board of Directors [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense		$ 15,600
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value						$ 18,000
Chief Financial Officer [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 0.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Remaining Number of Shares to Vest Each Month					25,000
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value												207,000
Chief Financial Officer [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense									51,750			207,000
Board of Directors and Vendors [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							307,777
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Period Extension							5 years
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member]
Allocated Share-based Compensation Expense										$ 77,418			$ 430,887
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										422,896			906,973
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0.76			$ 0.76
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0.33			$ 0.33
Board Of Directors [Member] | Outside of the 2007 Plan [Member]
Allocated Share-based Compensation Expense									$ 67,500			$ 202,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									132,354			407,704
Board Of Directors [Member] | Outside of the 2007 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.51			$ 0.51
Board Of Directors [Member] | Outside of the 2007 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.43			$ 0.43
Vendors and Employees [Member] | Outside of the 2007 Plan [Member]
Allocated Share-based Compensation Expense									$ 45,402			$ 187,476
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									144,317			689,846
Vendors and Employees [Member] | Outside of the 2007 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.67			$ 0.67
Vendors and Employees [Member] | Outside of the 2007 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.43			$ 0.43
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								5 years
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Outside of the 2007 Plan [Member] | Non-Qualified Stock Option [Member]
Allocated Share-based Compensation Expense	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.45
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value	$ 900,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Employment Agreement, Term	5 years

Note 5 - Share-based Compensa33

Note 5 - Share-based Compensation - Stock Options Issued Under the 2007 Equity Incentive Plan (Details) - The 2007 Equity Incentive Plan [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2016$ / shares	Dec. 31, 2015$ / shares
Options outstanding, Balance (in shares) | shares	9,916,586	10,241,086
Shares available, Balance (in shares) | shares		1,758,914
Weighted average price per share, Balance (in dollars per share)	$ 0.44	$ 0.46	$ 0.44	$ 0.44
Options outstanding, granted (in shares) | shares	340,000	40,000
Shares available, granted (in shares) | shares	(340,000)	(40,000)
Exercise price per share, granted (in dollars per share)		$ 0.45
Weighted average price per share, granted (in dollars per share)	$ 0.65	$ 0.45
Options outstanding, expired (in shares) | shares		(262,500)
Shares available, expired (in shares) | shares		262,500
Exercise price per share,Expired (in dollars per share)		$ 0.40
Weighted average price per share, expired (in dollars per share)		$ 0.40
Options outstanding, Balance (in shares) | shares	10,256,586	10,018,586
Shares available, Balance (in shares) | shares		1,981,414
Minimum [Member]
Exercise price per share, Balance (in dollars per share)	$ 0.22	$ 0.22	0.22	0.22
Exercise price per share, granted (in dollars per share)	0.39
Maximum [Member]
Exercise price per share, Balance (in dollars per share)	1.89	$ 1.89	$ 1.89	$ 1.89
Exercise price per share, granted (in dollars per share)	$ 0.69

Note 5 - Share-based Compensa34

Note 5 - Share-based Compensation - Stock Options Issued Outside of the 2007 Equity Incentive Plan (Details) - Outside of the 2007 Plan [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2016$ / shares	Dec. 31, 2015$ / shares
Options outstanding, Balance (in shares) | shares	20,148,766	19,394,975
Weighted average price per share, Balance (in dollars per share)	$ 0.51	$ 0.41	$ 0.40	$ 0.40
Options outstanding, granted (in shares) | shares	6,828,872	484,077
Weighted average price per share, granted (in dollars per share)	$ 0.46	$ 0.38
Options outstanding, exercised (in shares) | shares	3,866,630	(60,000)
Exercised, exercise price per share (in dollars per share)	$ 0.18	$ 0.25
Weighted average price per share, exercised (in dollars per share)	$ 0.18	$ 0.25
Options outstanding, Balance (in shares) | shares	19,244,379	19,819,052
Options outstanding, expired (in shares) | shares	(3,866,629)
Exercise price per share,Expired (in dollars per share)	$ 0.18
Weighted average price per share, expired (in dollars per share)	$ 0.18
Cashless exercise of stock options (in shares) | shares	(3,866,630)	60,000
Minimum [Member]
Exercise price per share, Balance (in dollars per share)	$ 0.18	$ 0.18	0.18	0.18
Exercise price per share, granted (in dollars per share)	0.43	0.33
Exercised, exercise price per share (in dollars per share)
Maximum [Member]
Exercise price per share, Balance (in dollars per share)	1	1	$ 1	$ 1
Exercise price per share, granted (in dollars per share)	0.67	$ 0.45
Exercised, exercise price per share (in dollars per share)

Note 5 - Share-based Compensa35

Note 5 - Share-based Compensation - Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Non Plan [Member]
Risk free interest rate, minimum	2.29%	1.77%
Risk free interest rate, maximum	2.40%	227.00%
Expected volatility, minimum	571.00%	641.00%
Expected volatility, maximum	601.00%	738.00%
Expected life in years (Year)	7 years	7 years
The 2007 Equity Incentive Plan [Member]
Risk free interest rate, minimum	2.31%	1.36%
Risk free interest rate, maximum	2.40%	1.77%
Expected volatility, minimum	578.00%	315.00%
Expected volatility, maximum	601.00%	641.00%
Expected life in years (Year)	7 years	5 years

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)	Sep. 26, 2017	May 24, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jul. 18, 2017	Dec. 30, 2016	Dec. 27, 2016	Sep. 17, 2016	Jul. 08, 2016	Dec. 31, 2015
Class of Warrant or Right, Issued During Period								2,499,933	5,670,996
Debt Instrument, Convertible, Conversion Price													$ 0.55
Class of Warrant or Right, Outstanding			21,775,047			20,035,114	18,036,889	21,775,047	18,036,889						13,779,438
Share Price											$ 0.83	$ 0.86	$ 0.70
Debt Conversion, Original Debt, Amount								$ 354,326	$ 272,032
Stock Issued During Period, Shares, Exercise of Warrants							1,150,000	510,000
Proceeds from Warrant Exercises							$ 355,000	$ 153,000	$ 355,000
Summer 2017 Unit Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.42
Debt Instrument, Convertible, Conversion Price		$ 0.42
Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,169,525					1,169,525
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.65
Class of Warrant or Right, Issued During Period		219,048	931,429	238,096
Class of Warrant or Right, Outstanding		619,048
Warrants Issued Concurrently With One Year Convertible Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	577,777									400,000	400,000			400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.42	$ 0.42								$ 0.65	$ 0.75			$ 0.65
Discount On Convertible Note Payable			$ 280,000					$ 280,000			$ 280,000			$ 160,000
Class of Warrant or Right, Increase (Decrease) in Securities Called by Warrants or Rights	177,777
Warrants Issued Concurrently to the Summer 2017 Unit Offering 2 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.42
Class of Warrant or Right, Issued During Period		314,285
Class of Warrant or Right, Outstanding		714,285
Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							4,455,413		4,455,413
Discount On Convertible Note Payable							$ 1,940,000		$ 1,940,000
Series A Warrants, Exercise Price 1 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							2,719,048		2,719,048
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.45		$ 0.45
Series A Warrants, Exercise Price 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,736,365		1,736,365
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.70		$ 0.70
Warrants Issued Concurrently with Line of Credit [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							300,000		300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.35		$ 0.35
Debt Instrument, Unamortized Discount							$ 237,405		$ 237,405
Warrant Issued in Exchange of Cancelled Line of Credit [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													515,583
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.70		$ 0.70				$ 0.70
Discount On Convertible Note Payable							$ 283,571		$ 283,571
Debt Conversion, Original Debt, Amount									$ 515,583
Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,169,525					1,169,525
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.65					$ 0.65
Warrants Issued Concurrently with Winter 2016 Unit Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					512,281
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.70
Class of Warrant or Right, Issued During Period					219,298	292,983
Discount On Convertible Note Payable			$ 491,200		$ 125,000			$ 491,200

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - $ / shares	3 Months Ended	9 Months Ended
	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016
Balance, outstanding (in shares)	18,036,889	20,035,114	13,779,438
Issued (in shares)		2,499,933	5,670,996
Exercised (in shares)		510,000	(1,150,000)
Exercised, price range (in dollars per share)		$ 0.30
Expired (in shares)		250,000	(263,545)
Balance, outstanding (in shares)	20,035,114	21,775,047	18,036,889
Exercised (in shares)		(510,000)	1,150,000
Expired (in shares)		(250,000)	263,545
Minimum [Member]
Balance, outstanding, price range (in dollars per share)	$ 0.125	$ 0.125	$ 0.125
Issued, price range (in dollars per share)		0.42	0.35
Exercised, price range (in dollars per share)			0.30
Expired, price range (in dollars per share)		0.25	0.55
Maximum [Member]
Balance, outstanding, price range (in dollars per share)	$ 1	1	1
Issued, price range (in dollars per share)		0.70	0.70
Exercised, price range (in dollars per share)			0.45
Expired, price range (in dollars per share)		$ 0.30	$ 0.75

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected life in years (Year)	5 years	5 years
Minimum [Member]
Risk free interest rate	1.71%	0.95%
Expected volatility	293.00%	311.00%
Maximum [Member]
Risk free interest rate	1.93%	1.36%
Expected volatility	297.00%	315.00%

Note 7 - Lincoln Park Transac39

Note 7 - Lincoln Park Transaction (Details Textual) - USD ($)	Aug. 25, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from Issuance of Common Stock			$ 22,500
Lincoln Park Capital Fund, LLC [Member]
Stock Purchase Agreement, Maximum Amount of Common Stock	$ 10,000,000
Stock Purchase Agreement, Maximum Shares of Common Stock to be Sold in a Single Business Day, Tier One	50,000
Stock Purchase Agreement, Maximum Shares of Common Stock to be Sold in a Single Business Day, Tier Two	75,000
Stock Purchase Agreement, Maximum Shares of Common Stock to be Sold in a Single Business Day, Tier Three	100,000
Stock Purchase Agreement, Maximum Shares of Common Stock to be Sold in a Single Business Day, Tier Four	200,000
Stock Purchase Agreement, Maximum Value of Total Common Stock to be Sold in a Single Business Day	$ 500,000
Stock Issued During Period, Shares, New Issues	488,998	51,100
Pro Forma Information, Stock Purchase Agreement, Stock Purchase Requested	$ 25,000
Pro Forma Information, Stock Purchase Agreement, Stock Purchase Requested, Additional Commitment Common Stock Issued	1,222
Pro Forma Information, Stock Purchase Agreement, Additional Commitment Shares, Numerator Value of Total Shares Calculation	$ 25,000
Pro Forma Information, Stock Purchase Agreement, Additional Commitment Shares, Denominator Value of Total Shares Calculation	$ 10,000,000
Pro Forma Information, Stock Purchase Agreement, Additional Commitment Shares, Multiplier of Total Shares Calculation	488,998
Proceeds from Issuance of Common Stock		$ 22,500
Stock Issued During Period, Purchased Shares, New Issues		50,000
Stock Issued During Period, Additional Commitment Shares, New Issues		1,100
Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]
Stock Purchase Agreement, Share Price, Tier One	$ 0.50
Stock Purchase Agreement, Share Price, Tier Two	0.74
Stock Purchase Agreement, Share Price, Tier Three	1.24
Lincoln Park Capital Fund, LLC [Member] | Minimum [Member]
Stock Purchase Agreement, Share Price, Tier Two	0.50
Stock Purchase Agreement, Share Price, Tier Three	0.75
Stock Purchase Agreement, Share Price, Tier Four	$ 1.25

Note 8 - Accounts Payable and40

Note 8 - Accounts Payable and Accrued Expenses (Details Textual) - USD ($)	Sep. 27, 2016	Jan. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Accrued Payroll Taxes, Possible Reduced Amount			$ 5,000
Accrued Bonuses, Current				$ 80,000
Chief Executive Officer [Member]
Accrued Bonuses, Current	$ 60,000
Bonuses Paid	$ 20,000	$ 40,000

Note 8 - Accounts Payable and41

Note 8 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts payable and accrued expenses	$ 277,411	$ 22,231
Payroll tax liability	137,500	137,500
Accrued officer bonus		80,000
Accrued interest	40,636	40,372
Total accounts payable and accrued expenses	$ 455,547	$ 280,103

Note 9 - Noncontrolling Inter42

Note 9 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($)	Aug. 04, 2017	Jul. 22, 2017	Dec. 30, 2015	Dec. 17, 2012	Apr. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from Issuance or Sale of Equity						$ 750,000
Consulting Services, Monthly Payment			$ 23,438
Consulting Services, Period of Services			4 years
Noncontrolling Interest, Increase from Subsidiary Equity Issuance						$ 1,020,400
Clyra Medical Technology Inc [Member]
Sale of Stock, Percentage of Ownership after Transaction			54.00%
Clyra Medical Technology Inc [Member]
Stock Issued During Period, Shares, New Issues	1,562.5
Clyra [Member]
Common Stock, Shares Owned	15,297.5
Noncontrolling Interest, Ownership Percentage by Parent	46.30%					46.30%
Clyra Medical Technology Inc [Member]
Investment Owned, Balance, Shares				100
Stock Issued During Period, Shares, New Issues	6,250
Preferred Stock, Dividend Rate, Percentage			8.00%
Preferred Shares Dividend, Period			5 years
Dividends Payable						$ 105,000
Shares Issued, Price Per Share	$ 160
Proceeds from Issuance of Private Placement	$ 1,000,000
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	$ 250,000
Clyra Medical Technology Inc [Member] | Former Member of Clyra's Management [Member]
Minority Interest Decrease From Redemption, Shares Purchased					500
Clyra Medical Technology Inc [Member] | Series A Preferred Stock [Member] | Sanatio [Member]
Proceeds from Issuance or Sale of Equity			$ 750,000
Clyra Medical Technology Inc [Member] | Each of 3 Individuals [Member]
Stock Issued During Period, Shares, New Issues				85
Sanatio [Member]
Stock Issued During Period, Shares, New Issues	1,690	1,690
Shares Issued, Price Per Share		$ 160
Sanatio [Member] | Clyra Medical Technology Inc [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			40.00%

Note 10 - Biolargo Engineerin43

Note 10 - Biolargo Engineering, Science and Technologies, LLC (Details Textual)	1 Months Ended
	Sep. 30, 2017USD ($)shares
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Increase To Monthly Budget for Employee Related Liabilities | $	$ 2
Deferred Compensation Arrangement with Individual, Requisite Service Period	5 years
Potential Ownership Percentage of Subsidiary Held by Subsidiary Employees Based on Performance	30.00%
Incentive Issuance Stipulations for Subsidiary Employees, Accounts Receivable Collected by Year One of Operation	90.00%
Incentive Issuance Stipulations for Subsidiary Employees, Profit Earned in Year One of Operation	10.00%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Leased Property in Knoxville, Tennessee for BioLargo Engineering, Science & Technologies, LLC [Member]
Lessee, Operating Lease, Term of Contract	3 years

Note 11 - Commitments and Con44

Note 11 - Commitments and Contingencies. (Details Textual)	May 02, 2017USD ($)$ / sharesshares	Dec. 30, 2015USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2017CAD	Oct. 01, 2017USD ($)	Oct. 01, 2017CAD
Consulting Services, Monthly Payment		$ 23,438
Consulting Services, Period of Services		4 years
Contractual Obligation			$ 1,125,024
Leased Office in Westminster California [Member]
Operating Lease, Monthly Cost			$ 8,630
Operating Lease, Annual Percentage Increase of Lease Costs			3.00%	3.00%
Property Under Lease at Oak Ridge [Member]
Operating Lease, Monthly Cost			$ 5,400
Property Under Lease in Alberta, Canada [Member]
Operating Lease, Monthly Cost | CAD				CAD 5,130
Lease Property in the United States of America [Member] | Subsequent Event [Member]
Operating Leases, Future Minimum Payments Due					$ 500,477
Lease Property in Canada [Member] | Subsequent Event [Member]
Operating Leases, Future Minimum Payments Due | CAD						CAD 46,170
President and Chief Executive Officer [Member]
Employment Agreement, Annual Base Compensation	$ 288,603
Employment Agreement, Car Allowance Monthly	$ 800
Employment Agreement, Option, Number of Shares, Expected to Grant | shares	3,731,322
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Employment Agreement, Common Stock, Expect to Grant, Subject to Lock-Up Agreement | shares	1,500,000
Employment Agreement, Lock-up Agreement, Successful Commercialization, Minimum Cash Receipt	$ 3,000,000
Employment Agreement, Lock-up Agreement, Minimum Revenue Recognized	$ 3,000,000
Employment Agreement, Term	5 years
President and Chief Executive Officer [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years

Note 12 - Subsequent Events. (D

Note 12 - Subsequent Events. (Details Textual) - USD ($)	Aug. 25, 2017	Nov. 06, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from Issuance of Common Stock				$ 22,500
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues	488,998		51,100
Proceeds from Issuance of Common Stock			$ 22,500
Stock Issued During Period, Additional Commitment Shares, New Issues			1,100
Subsequent Event [Member] | Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues		675,000
Proceeds from Issuance of Common Stock		$ 308,745
Stock Issued During Period, Additional Commitment Shares, New Issues		15,097